Treatment of aggressive non-Hodgkin's lymphoma in frail patients: cardiac comorbidities and advanced age
File(s)
Published version
Author(s)
Lugtenburg, Pieternella J
Lyon, Alexander R
Mark, Reinhard
Luminari, Stefano
Type
Journal Article
Abstract
The decisive factor in selecting a treatment regimen for a frail patient with aggressive non-Hodgkin's lymphoma is identifying whether a patient is fit enough to tolerate curative-intent anthracycline-containing regimens or too frail and therefore at risk of being undertreated. As cardiac comorbidities are an important contributor to both the health status and the selection of treatment, cardiovascular profiling and baseline risk stratification prior to treatment should be considered. Comprehensive geriatric assessment is an efficient means of identifying elderly patients with non-Hodgkin's lymphoma who may benefit from a curative treatment approach. If anthracycline-based therapy is not suitable, alternative treatment options are available in frail patients with cardiac comorbidities, but these must be adjusted to the patient's health status to achieve a maximal benefit–risk ratio.
Date Issued
2019-04-01
Date Acceptance
2019-01-22
Citation
FUTURE ONCOLOGY, 2019, 15 (11), pp.1197-1205
ISSN
1479-6694
Publisher
FUTURE MEDICINE LTD
Start Page
1197
End Page
1205
Journal / Book Title
FUTURE ONCOLOGY
Volume
15
Issue
11
Copyright Statement
© 2019 Pieternella J Lugtenburg. This work is licensed under the Attribution-NonCommercial-NoDerivatives 4.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-nd/4.0/
Identifier
http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000473704300004&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=1ba7043ffcc86c417c072aa74d649202
Subjects
Science & Technology
Life Sciences & Biomedicine
Oncology
cardiac comorbidities
elderly
frail
non-Hodgkin's lymphoma
treatment
B-CELL LYMPHOMA
COMPREHENSIVE GERIATRIC ASSESSMENT
OLDER CANCER-PATIENTS
NONPEGYLATED LIPOSOMAL DOXORUBICIN
ELDERLY-PATIENTS
CONVENTIONAL DOXORUBICIN
INTERNATIONAL-SOCIETY
HEART-FAILURE
CO-MORBIDITY
RISK-FACTORS
Publication Status
Published
Date Publish Online
2019-02-07